OBESITY AND POLYCYSTIC OVARY SYNDROME - PowerPoint PPT Presentation

1 / 39
About This Presentation
Title:

OBESITY AND POLYCYSTIC OVARY SYNDROME

Description:

... C-Peptide, testosterone and dehydroepiandrosterone-sulphate were measured in ... dehydroepiandrosterone-sulphat (nadbubreg vs. ovarijum) PCOS vs. zdrave zene ... – PowerPoint PPT presentation

Number of Views:603
Avg rating:3.0/5.0
Slides: 40
Provided by: dragan
Category:

less

Transcript and Presenter's Notes

Title: OBESITY AND POLYCYSTIC OVARY SYNDROME


1
  • Razvoj medicinskih nauka baziran je na
    istraivanju koje krajnjoj instanci delimicno
    mora da se obavi na ljudima.
  • Biomedicinsko istraivanje na ljudima deli se na
  • istraivanje ciji je cilj poboljanje
    dijagnostickih
  • i terapijskih postupaka
  • istraivanje sa iskljucivo naucnim ciljem, bez
  • direktne dobrobiti za dijagnostiku odnosno
    terapiju
  • subjekta istraivanja.

Cilj biomedicinskog istraivanja na ljudima
jeste poboljanje postojecih dijagnostickih,
terapijskih i profilaktickih metoda, kao i
rasvetljenje etiologije i patofiziologije
oboljenja.
2
Vrste klinickih istraivanja
Vrste klinickih istraivanja
  • Opservaciona
  • Intervenciona

3
Vrste klinickih istraivanja
  • Razjanjavanje etiologije i patogeneze
  • Procena i optimizacija dijagnostike
  • Procena efikasnosti terapije

4
ta je najbitnije definisati pre otpocinjanja
istraivanja?
  • Kontrolnu grupu
  • Eksperimentalne metode
  • Cilj istraivanja (primarni, sekundarni)
  • Istraivace ukljucene u studiju
  • Eksperimentalnu grupu

5
Odabrati odgovarajucu grupu ispitanika
Kriterijumi za ukljucenje u studiju
6
Kriterijumi koje sprecavaju ukljucenje
(ekskluzioni)
  • Slucajevi koji ne mogu da se procene (ergotest
    kod ispitanika bez noge)
  • Ne-ukljucenje iz bezbednosnih razloga (trudnoca)
  • Motivisanost bolesnika (non compliat)

7
Eksperimentalni dizajn
  • Paralelne grupe
  • Ukrteni tip (jedan pacijent)

8
Konsultacija eksperta i definisanje metoda se
radi pre otpocinjanja studije!
Analiza podataka
9
  • J Steroid Biochem. 1988 Dec31(6)995-9.
  • Androgen levels during sequential insulin
    euglycemic clamp studies in patients with
    polycystic ovary disease.Micic D, Popovic V,
    Nesovic M, Sumarac M, Dragasevic M, Kendereski A,
    Markovic D, Djordjevic P, Manojlovic D, Micic
    J.Clinic for Endocrinology, Diabetes and
    Diseases of Metabolism, University Clinical
    Center, Yugoslavia.It is postulated that
    insulin may play a role in the regulation of
    ovarian androgen production. In order to test the
    possible interrelation between serum insulin
    levels and androgen production, sequential
    euglycemic insulin clamp (Mode 91 on Biostator,
    insulin infusion rate 0.1 0.2 and 0.4 U/kg b.
    wt/h, each rate for 90 min, BC 80 mg/dl) was
    done in 6 patients with polycystic ovary disease
    and normal glucose tolerance. Insulin, C-Peptide,
    testosterone and dehydroepiandrosterone-sulphate
    were measured in 0, 70, 80, 90, 160, 170, 180,
    250, 260 and 270 min. Significant suppression of
    C-Peptide levels were achieved (0 min vs 270 min
    0.81 0.25 vs 0.15 0.20 nmol/l P less than
    0.05). Basal insulin as well as the mean plateau
    for each insulin infusion rate were as follows
    28 9 248 119 427 69 and 524 77
    microU/l. There was significant testosterone
    increase at the end of insulin infusion (0 vs 270
    min 4.8 1.2 vs 8.1 1.7 nmol/l P less than
    0.05). There were no significant changes in
    dehydroepiandrosterone-sulphate levels during
    clamp studies (0 vs 270 min 1055 133 vs 913
    114 ng/ml P greater than 0.05). It is concluded
    that acute insulin infusion under the condition
    of sequential euglycemic clamp could increase
    androgen production in the ovaries of patients
    with PCO.

10
Teorijske postavke
  • It is postulated that insulin may play a role in
    the regulation of ovarian androgen production.

11
  • Le virilisme pilaire et son association
  • a linsufficance glycolitique (diabete des
    femmes a barb) Achard C., Thiers J.
  • Bull Acad Natl Med 1921 86 51-64

12
Correlation of hyperandrogenism with
hyperinsulinism in polycystic ovarian disease
  • Burgen G.A., Givens R.J., Kitabchi A.E., J.
    Clin. Endocrinol. Metab. 1980 50 113-116

13
Revised 2003 consensus on diagnostic criteria of
PCOS
Fauser B., Human Reproduction 19 41-47, 2004.
14
Theories of the Pathogenesis of PCOS
Salehi M. et al., Metabolism 2004 53 358-376
15
How common is it ?
  • Common endocrine disorder in pre-menopausal
    women 5-20 Hoeger K, Obstet Gynecol Clin North
    Am 2001 28 85-97
  • 50 of PCOS women are overweightGambineri A et
    al., Int J Obes Relat Metab Disord 2002
    26883-896

16
The role of Obesity in PCOS
  • Enhancement of hyperinsulinemia
  • The role of leptin
  • The enzymatic activity of adipose tissue in
    relation to steroid hormone metabolism

17
  • Syndrome X
  • Resistance to insulin stimulated glucose uptake
  • Glucose intolerance
  • Hyperinsulinaemia
  • Increased very-low density lipoprotein
    triglycerides
  • Decreased high-density lipoprotein cholesterol
  • Hypertension


18
Criteria for the Metabolic Syndrome in PCOS
Fauser B., Human Reproduction 19 41-47, 2004.
19
MARKERS OF THE RISK OF CORONARY HEART DISEASE
  • HYPERINSULINEMIC WOMEN WITH POLYCYSTIC OVARY
    SYNDROME MAY REPRESENT THE FEMALE COMPONENT OF
    REAVENS SYNDROME X
  • Jacobs H.S. Polycystic Ovary Syndrome the
    present positionGynecol Endocrinol
    199610427-433.

20
Health consequences of PCOS
  • Syndrome X Elevated VLDL triglycerides Decre
    ased HDL cholesterol Hypertension Insulin
    resistance Hyperinsulinemia Glucose
    intolerance
  • Syndrome XXPCOS Endometrial cancer Breast
    cancer (?)Kazer R.R., Seminars in Reproductive
    Endocrinology, 1997 15193-194.

21
Zakljucci hipoteze Sy PCO DUAL DEFECT
(Poretsky Piper, 1994)
  • Dva nezavisna geneticka defekta
  • Povecanje LH sekrecije
  • Insulinska rezistencija
  • Razvoj Sy PCO je rezultatSinergistickog
    delovanja povienih LH nivoa i hiperinsulinemije
    na jajnik.

22
(No Transcript)
23
Periferna insulinska rezistencija
Folikularni IGFBPs
Povisena sekrecija LH
Izostanak FSH efekta
Serumski insulin
Serumski IGFBP-1 Slobodni IGF-1
Povecano stvaranje androgena u teki
Defektna folikularna maturacija
Aciklicno stvaranje estrogena
HIPERANDROGENIZAM
ANOVULACIJA
PATOFIZIOLOGIJA Sy PCO
24
PATHWAYS LEADING TO ANDROGEN EXCESS IN PCOS
Tscichorozidou T et al.., Clin Endocrinol 60
1-17, 2004
25
Definisanje ciljeva
  • The aim of the study was to test the possible
    interrelation between serum insulin levels and
    androgen production.

26
Insulin Effects Related to Ovarian Function
Salehi M. et al., Metabolism 2004 53 358-376
27
Dve karakteristike Sy PCO
  • Hiperinsulinemijska insulinska rezistencija
  • Povecana aktivnost ovarijalnog citohroma
    P450c17??
  • Hiperinsulinemija stimulie ovaj enzim
  • direktno
  • indirektno, povecavajuci sekreciju gonadotropina
  • Urodjena abnormalnost ?

28
Insulin and Cytochrome P450c17a
  • Cytochrome P450c17a key enzyme in the
    biosynthesis of ovarian androgens
  • Bifunctional enzime - 17a-hydroxylase- 17,
    20-lyase
  • Many women with PCOS increased ovarian cytohrome
    P450c17a activity
  • Hallmark exaggerated serum 17a-hydroxyprogestero
    ne response to stimulation by GnRH agonist (
    nafarelin buserelin leuprolide )

29
Hipofiza
LH

Celija teke
?
HOLESTEROL
PREGNENOLON
PROGESTERON
?

17 a hidroksilaza
INSULIN
P450c17a
17 a HIDROKSIPROGESTERON
17, 20 - liaza
ANDROSTENEDION
17b reduktaza
TESTOSTERON
STIMULACIJA OVARIJALNOG STVARANJA ANDROGENA
INSULINOM
30
Postulated role for insulin-sensitising agents
Harborne L et al., Lancet 2003 361 1894-1901
31
Znacaj kontrolne grupe
  • dehydroepiandrosterone-sulphat (nadbubreg vs.
    ovarijum)
  • PCOS vs. zdrave zene

32
PCOS gen hipoteza
  • Insulin nije dovoljno visok u normalnih ena ili
    insulin ne regulie ovarijalne androgene pod
    fiziolokim uslovima
  • Atraktivno objanjenje je da normalne ene nemaju
    genetsku predispoziciju za stimulatorno delovanje
    insulina na ovarijalne androgene
  • Nestler JE Insulin resistance effects on sex
    hormones and ovulation in the Polycystic Ovary
    Syndrome,
  • U Contemporary Endocrinology Insulin
    Resistance, 1999 347-365.

33
Eksperiementalni protokol
  • Definisanje eksperiementa
  • Sequential euglycemic insulin clamp (Mode 91 on
    Biostator, insulin infusion rate 0.1 0.2 and
    0.4 U/kg b. wt/h, each rate for 90 min,) was done
    in 6 patients with polycystic ovary disease and
    normal glucose tolerance. Insulin, C-Peptide,
    testosterone and dehydroepiandrosterone-sulphate
    were measured in 0, 70, 80, 90, 160, 170, 180,
    250, 260 and 270 min.
  • Sigurnost za pacijenta
  • BC 80 mg/dl

34
Micic D. et al. J Steroid Biochem 1988
31995-999.
TESTOSTERONE (nmol/l)
Insulin (U/kg/h)
0.4
0.2
0.1
0 70 80 90 160 170
180 250 260 270
t (min)
35
Zakljucak
  • It is concluded that acute insulin infusion under
    the condition of sequential euglycemic clamp
    could increase androgen production in the ovaries
    of patients with PCO.

36
2 Phenotypes Low LH- High Insulin High LH- Low
Insulin Barbieri R., 1988
37
Minimal model - IVGTT
Plasma glucose (mg/dl)
Plasma insulin (mU/l)
M. Sumarac-Dumanovic,, Insulin secretion and
action in PCOS, PhD thesis, Belgrade, 2000
38
Insulin sensitivity in patients with PCOS and in
controls
10
P lt 0.05 BMI p lt 0.05 IN-BMI IN-WHR
8
Si
6
4
2
0
controls
PCOS
M. Sumarac-Dumanovic,, Insulin secretion and
action in PCOS, PhD thesis, Belgrade, 2000
39
Korelacija testosterona i insulinske senzitivnsti
(Si) u SyPCO
10
8
6
SI
4
gojazne SyPCO
2
negojazne SyPCO
Sve SyPCO
r -0,258, plt0,05
0
12
10
8
6
4
2
0
Testosteron (nmol/l)
Write a Comment
User Comments (0)
About PowerShow.com